ArticleDermatology and therapy2026
Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02786186 (A Registry of Patients With Moderate to Severe Chronic Plaque Psoriasis in Canada and Latin AmErica), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Registry of Patients With Moderate to Severe Chronic Plaque Psoriasis in Canada and Latin AmErica (LACan)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Psoriasis Epidemiology Screening Tool (PEST) is a 5-item questionnaire designed to identify patients with psoriasis who have co-existing psoriatic arthritis (PsA). This analysis investigated the longitudinal performance of the PEST questionnaire in the prospective, observational PURE registry.
methodsThe PURE registry included 2132 patients with psoriasis who completed the PEST at baseline, 3 and 6 months then every 6 months for 5 years. Baseline diagnostic performance was assessed using existing PsA diagnoses as the reference standard. PEST positivity changes over time were assessed, and regression models determined factors linked to baseline PEST status and conversion from negative to positive. Cronbach's alpha assessed internal consistency, while exploratory factor analysis evaluated changes in individual PEST questions over time.
resultsAt baseline, 906 patients (42.5%) were PEST positive and 373 (17.5%) had PsA, for a diagnostic sensitivity of 89% and a negative predictive value of 97%. Overall, the proportion of patients who became PEST positive increased from 42.5% at baseline to 63.9% at 5 years, rising from 89.0% to 95.8% and 32.6% to 57.2% respectively in those who were PEST positive or negative at baseline. Regression modeling confirmed that increased age (p < 0.0001), weight > 90 kg (p < 0.0001), female sex (p = 0.0107) and prior biologic exposure (p < 0.0001) were related to PEST status at baseline and of which the first three were also related to change from negative to positive during follow-up. Cronbach's alpha showed high internal consistency of the PEST questionnaire (0.693). Exploratory factor analysis found that responses to questions 1, 2, 4, and 5 increased over time, while question 3 decreased. Eigenvalues revealed consistent dominance of question 1 and two-factor structure in the questionnaire.
conclusionThe PEST questionnaire is an informative, easy-to-use tool which may be useful to monitor and identify patients with psoriasis who are at risk of PsA over time.
trial registrationClinicalTrials.gov ID NCT02786186; date of registration May 30, 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.